Professional Role and Expertise
Adam Gwozdz holds the position of Medical Director at Stryker, specifically within the Inari Division, which focuses on cardiovascular and venous therapies. His core professional expertise spans medical affairs leadership with a specialization in cardiovascular and venous disease therapies. His responsibilities include the development and execution of medical affairs strategies, focusing on clinical development, evidence generation, and regulatory affairs that support innovation aimed at improving patient outcomes in vascular medicine.
He has over 12 years of experience in academic vascular surgery and is known for advancing the field of venous surgery and the clinical management of conditions such as deep venous thrombosis (DVT) and venous stenting. His substantial clinical and research background underpins his role in translating cutting-edge academic knowledge into commercial medical solutions within Stryker.
Key Achievements and Recognition
- In October 2024, Adam Gwozdz was appointed the first Inari Innovation Fellow at Inari Medical, prior to and throughout its acquisition by Stryker, highlighting his recognized leadership in innovation within the peripheral vascular space.
- In February 2025, he was awarded the Arris & Gale Lectureship by The Royal College of Surgeons of England, a prestigious honor underscoring his professional contributions to vascular surgery and medical science.
- He is a Clinical Lecturer in Vascular Surgery at Imperial College London, with a scholarly footprint demonstrated by over 1,100 citations in peer-reviewed publications focused on venous surgery, deep venous thrombosis, and platelet biochemistry.
Role within Stryker and Strategic Impact
Adam plays a critical role leading the medical affairs strategy for cardiovascular and venous therapies at Stryker's Inari Division. This division was established through Stryker’s acquisition of Inari Medical in February 2025 for approximately $4.9 billion, marking a significant expansion of Stryker’s portfolio into the high-growth peripheral vascular segment. This acquisition is a strategic initiative by Stryker to provide "life-saving solutions" to patients with peripheral vascular diseases, and Adam’s role is central to integrating Inari’s clinical innovations within the broader Stryker platform.
His medical leadership is directly linked to Stryker’s efforts to enhance volume and procedural quality through best-in-class clinical evidence and regulatory compliance. Adam has been actively engaged in clinical evidence generation and medical affairs dissemination to support product launches and market adoption of new vascular therapies under the Inari brand.
Industry Influence and Professional Network
- Adam’s professional trajectory includes strong ties to academic and clinical communities, facilitating multidisciplinary collaborations aimed at limb salvage and vascular disease treatment.
- His publications and clinical lectures contribute to ongoing medical education and the advancement of venous and cardiovascular therapy practices internationally.
- His blend of deep clinical insight and strategic medical affairs expertise uniquely positions him to influence both internal R&D direction and external stakeholder engagement including key opinion leaders in vascular medicine.
Stryker’s Business Context Related to Adam’s Division
- Stryker’s acquisition of Inari Medical is part of a broader mergers and acquisitions strategy that accelerated in 2024-2025, including notable deals like those for Vertos Medical and care.ai. These moves aim to diversify and strengthen Stryker’s product offerings in cardiovascular, neurovascular, and interventional pain management sectors.
- The Inari Division is focused on deploying new peripheral vascular devices, including the launch of novel thrombectomy systems (e.g., InThrill®) and other technologically advanced treatment options for venous disease.
- Stryker’s corporate emphasis on evidence-based innovation and clinical outcomes improvement aligns with Adam’s mandate to guide medical strategy, regulatory compliance, and real-world evidence initiatives within this key vascular segment.
This profile of Adam Gwozdz, MD PhD reveals a senior medical affairs leader with robust academic credentials and a pivotal role in the integration and advancement of Stryker’s peripheral vascular division following the major acquisition of Inari Medical. His expertise in cardiovascular and venous therapies, combined with recognized clinical and academic achievements, situates him as a critical driver of Stryker’s innovation agenda in this high-growth therapeutic area.
